Health News Roundup: China gives conditional OK to its first self-developed Alzheimer's drug
Following is a summary of current health news briefs.
China gives conditional OK to its first self-developed Alzheimer's drug
China has granted conditional approval to its first self-developed treatment for Alzheimer's disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug. Oligomannate, which uses extract from marine brown algae as raw material, received a conditional green light to treat mild-to-moderate level AD, the National Medical Products Administration (NMPA) said in a statement on its website late on Saturday.
(With inputs from agencies.)
- READ MORE ON:
- China
- drugmakers
- Alzheimer
- Oligomannate
ALSO READ
Biotech trade association to split with China's WuXi AppTec
China's foreign minister to visit Australia next week as ties improve
Taiwan, China dispatch teams to join boat rescue mission near Taiwan-controlled islands
Probe begins after 7 killed, 27 injured in fried chicken shop explosion in China
Taiwan, China join rescue mission near sensitive islands